Foot in door for first-in-class antibody-drug conjugate

23 April 2020
fda_big

Immunomedics (Nasdaq: IMMU) has at last won approval for the first Trop-2 targeting antibody-drug conjugate, Trodelvy (sacituzumab govitecan-hziy).

The option was given an accelerated approval for people with metastatic triple-negative breast cancer (mTNBC), in the third-line setting.

It hasn’t been a straight road to approval for the New Jersey, USA-based firm, with the US regulator earlier  rejecting a bid for accelerated approval, on the basis of quality control problems, including a data integrity breach.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology